Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Edoxaban Tosylate

FDA-approved product (tablet, oral), marketed as Savaysa.

Registered studies
22
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Edoxaban Tosylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Atrial fibrillation
  • Deep vein thrombosis
  • Pulmonary embolism
  • Recurrent thrombophlebitis
  • Stroke
  • Venous thromboembolism

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Direct factor xa inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA62.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli52.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae38.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

22registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Edoxaban Tosylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-4.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Edoxaban Tosylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty

    NCT01203098 · start 2008-07

    Registered record
    Registry ID
    NCT01203098
    Conditions
    Venous Thromboembolism; Thromboembolism; Thrombosis; Embolism and Thrombosis; Deep Vein Thrombosis; Arthroplasty, Replacement, Hip
    Interventions
    DU-176b 15mg; DU-176b 30mg; Enoxaparin sodium 20 mg (=2000IU)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-07
    Completion
    2009-06
    Enrolment
    264

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVenous Thromboembolism; Thromboembolism; Thrombosis; Embolism and Thrombosis +2 more
    InterventionDU-176b 15mg; DU-176b 30mg; Enoxaparin sodium 20 mg (=2000IU)
    PhasePhase 2
    Registry statusCompleted

  • DU-176b Phase 2 Dose Finding Study in Subjects With Non-valvular Atrial Fibrillation

    NCT00806624 · start 2007-10

    Registered record
    Registry ID
    NCT00806624
    Conditions
    Atrial Fibrillation; Stroke
    Interventions
    DU-176b tablets; DU-176b tablets; Warfarin tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-10
    Completion
    2009-11
    Enrolment
    234

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation; Stroke
    InterventionDU-176b tablets; DU-176b tablets; Warfarin tablets
    PhasePhase 2
    Registry statusCompleted

  • A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation

    NCT00504556 · start 2007-06

    Registered record
    Registry ID
    NCT00504556
    Conditions
    Atrial Fibrillation; Thromboembolism
    Interventions
    Edoxaban (DU-176b); Edoxaban (DU-176b); Edoxaban (DU-176b); Edoxaban (DU-176b); warfarin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-06
    Completion
    2008-06
    Enrolment
    1,146

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation; Thromboembolism
    InterventionEdoxaban (DU-176b); Edoxaban (DU-176b); Edoxaban (DU-176b); Edoxaban (DU-176b) +1 more
    PhasePhase 2
    Registry statusCompleted

  • Late Phase 2 Study of DU-176b in Patients With Non-Valvular Atrial Fibrillation

    NCT00829933 · start 2007-03

    Registered record
    Registry ID
    NCT00829933
    Conditions
    Atrial Fibrillation
    Interventions
    DU-176b tablets; Warfarin potassium tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-03
    Completion
    2008-09
    Enrolment
    536

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation
    InterventionDU-176b tablets; Warfarin potassium tablets
    PhasePhase 2
    Registry statusCompleted

  • A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty

    NCT01203072 · start 2006-07

    Registered record
    Registry ID
    NCT01203072
    Conditions
    Venous Thromboembolism; Deep Vein Thrombosis; Total Knee Arthroplasty
    Interventions
    DU-176b; DU-176b; DU-176b; DU-176b; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-07
    Completion
    2008-07
    Enrolment
    523

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVenous Thromboembolism; Deep Vein Thrombosis; Total Knee Arthroplasty
    InterventionDU-176b; DU-176b; DU-176b; DU-176b +1 more
    PhasePhase 2
    Registry statusCompleted

  • A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery

    NCT00398216 · start 2006-05

    Registered record
    Registry ID
    NCT00398216
    Conditions
    Thrombosis; Hip Replacement
    Interventions
    DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-05
    Completion
    2007-06
    Enrolment
    903

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThrombosis; Hip Replacement
    InterventionDU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor
    PhasePhase 2
    Registry statusCompleted

  • Study of the Efficacy and Safety of DU-176b in Preventing Blood Clots in Patients Undergoing Total Hip Replacement

    NCT00107900 · start 2005-01

    Registered record
    Registry ID
    NCT00107900
    Conditions
    Arthroplasty, Replacement, Hip; Thrombosis
    Interventions
    DU-176b
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-01
    Completion
    2005-12
    Enrolment
    606

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionArthroplasty, Replacement, Hip; Thrombosis
    InterventionDU-176b
    PhasePhase 2
    Registry statusCompleted